Benzinga - by Lisa Levin, Benzinga Editor.
The Dow Jones closed lower by over 150 points on Thursday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga's insider transactions platform.
BioRestorative Therapies
- The Trade: BioRestorative Therapies, Inc. (NASDAQ: BRTX) Director, VP of Research and Development Francisco Silva acquired a total of 4,954 shares an average price of $2.22. To acquire these shares, it cost around $10,998.
- What’s Happening: BioRestorative Therapies announced a $2.1 million registered direct offering.
- What BioRestorative Therapies Does: BioRestorative Therapies Inc is a biotechnology company based in the United States. It focuses on the development of regenerative medicine products and therapies using cell and tissue protocols, primarily involving adult (non-embryonic) stem cells.
- The Trade: Telos Corporation (NASDAQ: TLS) Chairman and CEO John B Wood acquired a total of 120,187 shares at an average price of $2.20. The insider spent around $263,907.
- What’s Happening: Telos was awarded a five-year contract with Defense Information Systems Agency.
- What Telos Does: Telos Corp offers technologically advanced, software-based security solutions that empower and protect the world's security-conscious organizations against rapidly evolving, sophisticated and pervasive threats.
- The Trade: Coeptis Therapeutics Holdings, Inc. (NASDAQ: COEP) Director Chris Calise acquired a total of 11,582 shares at an average price of $0.94. To acquire these shares, it cost around $10,879.
- What’s Happening: Coeptis Therapeutics filed FDA 513(g) submission for CD38 in vitro companion diagnostic.
- What Coeptis Therapeutics Does: Coeptis Therapeutics Holdings Inc is a biopharmaceutical company developing cell therapy platforms for patients with cancer.
Don’t forget to check out our premarket coverage here
ReWalk Robotics
- The Trade: ReWalk Robotics Ltd. (NASDAQ: RWLK) Director Joseph Turk acquired a total of 1,616 shares at an average price of $0.62. The insider spent $994 to buy those shares.
- What’s Happening: ReWalk Robotics posted downbeat quarterly results.
- What ReWalk Robotics Does: ReWalk Robotics Ltd is an Israel based medical device company. It is engaged in designing, developing and commercializing the Rewalk systems which are exoskeletons allowing wheelchair-bound individuals to stand and walk once again.